American Journal of Kidney Diseases
Volume 55, Issue 3 , Pages 485-496 , March 2010

Decreased Kidney Function of Unknown Cause in Nicaragua: A Community-Based Survey

  • Cecilia Torres, MD

      Affiliations

    • Research Centre on Health, Work and Environment, National Autonomous University of Nicaragua at León, León, Nicaragua
    • Occupational and Environmental Medicine, Department of Medical Sciences, Uppsala Universitet, Uppsala, Sweden
    • Corresponding Author InformationAddress correspondence to Cecilia Torres, MD, CISTA, Campus Médico, UNAN-León, León, Nicaragua
    • ,
  • Aurora Aragón, PhD

      Affiliations

    • Research Centre on Health, Work and Environment, National Autonomous University of Nicaragua at León, León, Nicaragua
    • ,
  • Marvin González, MSc

      Affiliations

    • Research Centre on Health, Work and Environment, National Autonomous University of Nicaragua at León, León, Nicaragua
    • ,
  • Indiana López, PhD

      Affiliations

    • Research Centre on Health, Work and Environment, National Autonomous University of Nicaragua at León, León, Nicaragua
    • ,
  • Kristina Jakobsson, PhD

      Affiliations

    • Department of Occupational and Environmental Medicine, Lund University, Lund, Sweden
    • ,
  • Carl-Gustaf Elinder, PhD

      Affiliations

    • Department of Renal Medicine, Karolinska University Hospital, Sweden
    • ,
  • Ingvar Lundberg, PhD

      Affiliations

    • Occupational and Environmental Medicine, Department of Medical Sciences, Uppsala Universitet, Uppsala, Sweden
    • ,
  • Catharina Wesseling, PhD

      Affiliations

    • Occupational and Environmental Medicine, Department of Medical Sciences, Uppsala Universitet, Uppsala, Sweden
    • Central American Institute for Studies on Toxic Substances, Universidad Nacional, Heredia, Costa Rica

Received 3 August 2009 ,Accepted 2 December 2009.

References 

  1. Centers for Disease Control and Prevention (CDC). Prevalence of chronic kidney disease and associated risk factors—United States, 1999-2004. MMWR Morbid Mortal Wkly Rep. 2007;56(8):161–165
  2. Arogundade FA, Barsoum RS. CKD prevention in Sub-Saharan Africa: a call for governmental, nongovernmental, and community support. Am J Kidney Dis. 2008;51(3):515–523
  3. Cusumano AM, Gonzalez Bedat MC. Chronic kidney disease in Latin America: time to improve screening and detection. Clin J Am Soc Nephrol. 2008;3(2):594–600
  4. Eknoyan G, Lameire N, Barsoum R, et al. The burden of kidney disease: improving global outcomes. Kidney Int. 2004;66(4):1310–1314
  5. Hamer RA, El Nahas AM. The burden of chronic kidney disease. BMJ. 2006;332(7541):563–564
  6. Hossain MP, Goyder EC, Rigby JE, El Nahas M. CKD and poverty: a growing global challenge. Am J Kidney Dis. 2009;53(1):166–174
  7. Meguid El Nahas A, Bello AK. Chronic kidney disease: the global challenge. Lancet. 2005;365(9456):331–340
  8. Durante-Mangoni EGA, Utili R, Falagas ME. Do we still need the aminoglycosides?. Int J Antimicrob Agents. 2008;Oct 29;33(3):201–205
  9. Griffin MR, Yared A, Ray WA. Nonsteroidal antiinflammatory drugs and acute renal failure in elderly persons. Am J Epidemiol. 2000;151(5):488–496
  10. Martínez-Salgado CL-HF, López-Novoa JM. Glomerular nephrotoxicity of aminoglycosides. Toxicol Appl Pharmacol. 2007;223(1):86–98
  11. Zhang L, Zhang P, Wang F, et al. Prevalence and factors associated with CKD: a population study from Beijing. Am J Kidney Dis. 2008;51(3):373–384
  12. Amato D, Alvarez-Aguilar C, Castaneda-Limones R, et al. Prevalence of chronic kidney disease in an urban Mexican population. Kidney Int Suppl. 2005;97:S11–S17
  13. Wanigasuriya KP, Peiris-John RJ, Wickremasinghe R, Hittarage A. Chronic renal failure in North Central Province of Sri Lanka: an environmentally induced disease. Trans R Soc Trop Med Hyg. 2007;101(10):1013–1017
  14. Cerdas M. Chronic kidney disease in Costa Rica. Kidney Int Suppl. 2005;97:S31–S33
  15. Debelle FD, Vanherweghem JL, Nortier JL. Aristolochic acid nephropathy: a worldwide problem. Kidney Int. 2008;74(2):158–169
  16. Grollman AP, Shibutani S, Moriya M, et al. Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc Natl Acad Sci U S A. 2007;104(29):12129–12134
  17. Hassen W, Abid S, Achour A, Creppy E, Bacha H. Ochratoxin A and beta2-microglobulinuria in healthy individuals and in chronic interstitial nephropathy patients in the centre of Tunisia: a hot spot of ochratoxin A exposure. Toxicology. 2004;199(2-3):185–193
  18. Lai MN, Lai JN, Chen PC, et al. Increased risks of chronic kidney disease associated with prescribed Chinese herbal products suspected to contain aristolochic acid. Nephrology (Carlton). 2009;14(2):227–234
  19. Tanaka A, Nishida R, Yoshida T, Koshikawa M, Goto M, Kuwahara T. Outbreak of Chinese herb nephropathy in Japan: are there any differences from Belgium?. Intern Med. 2001;40(4):296–300
  20. Bandara JM, Senevirathna DM, Dasanayake DM, et al. Chronic renal failure among farm families in cascade irrigation systems in Sri Lanka associated with elevated dietary cadmium levels in rice and freshwater fish (tilapia). Environ Geochem Health. 2008;30(5):465–478
  21. Barbier O, Jacquillet G, Tauc M, Cougnon M, Poujeol P. Effect of heavy metals on, and handling by, the kidney. Nephron Physiol. 2005;99(4):105–110
  22. Hellstrom L, Elinder CG, Dahlberg B, et al. Cadmium exposure and end-stage renal disease. Am J Kidney Dis. 2001;38(5):1001–1008
  23. Lin JL, Lin-Tan DT, Hsu KH, Yu CC. Environmental lead exposure and progression of chronic renal disease in patients without diabetes. N Engl J Med. 2003;348(4):277–286
  24. Yu CC, Lin JL, Lin-Tan DT. Environmental exposure to lead and progression of chronic renal diseases: a four-year prospective longitudinal study. J Am Soc Nephrol. 2004;15(4):1016–1022
  25. Cuadra S, Jakobsson K, Hogstedt C, Wesseling C. Chronic Kidney Disease in Central America (Chronic Kidney Disease: Assessment of Current Knowledge and Feasibility for Regional Research Collaboration in Central America, Section 1, vol 2). Heredia, Costa Rica: SALTRA; 2006;
  26. Callejas L, Alonso CD, Mendoza B. Insuficiencia renal crónica: una prioridad en salud pública, en la zona de la costa del pacífico de Nicaragua, Mayo-Septiembre 2003. SALTRA, ed. In: Chronic Kidney Disease: Assessment of Current Knowledge and Feasibility for Regional Research Collaboration in Central America, Section 1, vol 2. 1st ed.. Heredia, Costa Rica: Salud y Trabajo en América Central; 2006;p. 26–27
  27. Callejas L, Alonso CD, Mendoza B. Insuficiencia renal crónica (IRC) en trabajadores de caña de azúcar, El Viejo, Chinandega. SALTRA, ed. In: Chronic Kidney Disease: Assessment of Current Knowledge and Feasibility for Regional Research Collaboration in Central America, vol 2. 1st ed.. Heredia, Costa Rica: Salud y Trabajo en América Central; 2006;p. 25–26
  28. Marín J, Berroterán J. Insuficiencia renal crónica: Cuadro clínico y situación epidemiológica en Nicaragua. SALTRA, ed. In: Chronic Kidney Disease: Assessment of Current Knowledge and Feasibility for Regional Research Collaboration in Central America, Section 1, vol 2. 1st ed.. Heredia, Costa Rica: Salud y Trabajo en América Central; 2006;p. 18–21
  29. Domínguez J, Montoya Pérez C, Jansá J. Análisis de prevalencia y determinantes de la insuficiencia renal crónica de la costa del Océano Pacífico: Sur de México, Guatemala, El Salvador y Honduras. SALTRA, ed. In: Chronic Kidney Disease: Assessment of Current Knowledge and Feasibility for Regional Research Collaboration in Central America, Section 1, vol 2. 1st ed.. Heredia, Costa Rica: Salud y Trabajo en América Central; 2006;p. 23–24
  30. Trabanino RG, Aguilar R, Silva CR, Mercado MO, Merino RL. [End-stage renal disease among patients in a referral hospital in El Salvador]. Rev Panam Salud Publica. 2002;12(3):202–206
  31. Levey AS, Coresh J, Greene T, et al. Chronic Kidney Disease Epidemiology Collaboration Using standardized serum creatinine values in the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247–254
  32. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: evaluation, classification, and stratification. Am J Kidney Dis. Feb 2002;39(2 suppl 1):S1–S266
  33. Roche Diagnostics. Creatinine Jaffé Gen.2, Compensated Method for Serum and Plasma. Vol V 1 ES Mannheim, Germany: Roche Diagnostics; 2006;
  34. Wyss M, Kaddurah-Daouk R. Creatine and creatinine metabolism. Physiol Rev. 2000;80(3):1107–1213
  35. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298(17):2038–2047
  36. Hallan SI, Coresh J, Astor BC, et al. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol. 2006;17(8):2275–2284
  37. Gracia-Trabanino R, Dominguez J, Jansa JM, Oliver A. [Proteinuria and chronic renal failure in the coast of El Salvador: detection with low cost methods and associated factors]. Nefrologia. 2005;25(1):31–38
  38. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–1305

 Originally published online as doi:10.1053/j.ajkd.2009.12.012 on February 1, 2010.

PII: S0272-6386(09)01587-X

doi: 10.1053/j.ajkd.2009.12.012

American Journal of Kidney Diseases
Volume 55, Issue 3 , Pages 485-496 , March 2010

Article Tools

* Image Usage & Resolution